Retail blockbusters, then specialty drugs. Now a new era of mega-blockbusters | Asembia AXS26 Summit
The pharmaceutical industry is entering an era of mega-blockbusters, drugs with annual sales of $10 billion or more, that ...
As AstraZeneca braces for the impact of the U.S. “most favored nation” drug pricing policy, CEO Pascal Soriot suggests that a ...
On Tuesday, Novartis NVS CEO Vas Narasimhan said the Trump administration's "most favored nation" (MFN) drug pricing policy ...
Pharmalittle: We’re reading about warnings over Trump’s MFN plan, Purdue Pharma sentencing, and more
The Novartis CEO warned that Trump's drug pricing policy poses a “very difficult situation” and the reality will soon catch ...
AstraZeneca and GSK, the U.K.'s second and ninth most valuable companies, both saw first-quarter profits beat expectations early Wednesday.
Today, President Donald J. Trump announced the 17th agreement with a major pharmaceutical manufacturer, Regeneron, to lower prescription drug prices that Americans pay for some of the world’s most ...
The final major drugmaker President Donald Trump had pressed to accept a most-favored-nation deal has signed an agreement ...
ADVI Health’s Lindsay Greenleaf discusses how most-favored-nation drug pricing is playing out among specialty drugs. Drug ...
With Regeneron poised to announce a drug pricing deal with the White House Thursday, all 17 companies targeted in a round of ...
Recent GlobalData POLI analysis showed a 35% decline in pharmaceutical launches across Europe in the ten months after the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results